Smart drug schedule may improve melanoma treatment
NCT ID NCT03543969
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tested a new way of giving three drugs (encorafenib, binimetinib, and nivolumab) to people with advanced BRAF-mutant melanoma. Instead of taking the drugs every day, participants followed an on/off schedule to see if it could control the cancer while reducing side effects. The study enrolled 14 adults with stage IIIC-IV melanoma that could not be removed by surgery.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRAF V600E MUTANT UNRESECTABLE MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, 33612, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can your genes predict your melanoma risk?
- A UV photo and a cheek swab may be the keys to stopping sunburn before it starts
- Night shift workers' skin may struggle to fix sun damage, study suggests
- New melanoma drug aims to match Keytruda's success
- Could a cheaper copy of keytruda work just as well against cancer?
- Astrophysics meets dermatology: AI that maps moles like stars to catch melanoma early